Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Jaundice caused by rifampicin: 3 cases].

B Taillan1, R M Chichmanian, J G Fuzibet

  • 1Service de médecine interne I, hôpital de Cimiez, Nice.

La Revue De Medecine Interne
|September 1, 1989
PubMed
Summary

Rifampicin treatment can cause cholestatic hepatitis, a liver condition characterized by bile flow obstruction. This adverse effect was observed in three patients without prior liver issues, suggesting a direct link to the drug.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Severe intestinal obstruction due to Strongyloides stercoralis in a pregnant woman.

Medecine et maladies infectieuses·2017
Same author

[Efficacy of autologous peripheral blood stem cell transplantation (auto-PBSCT) on the neuropathic manifestations in POEMS syndrome].

Revue neurologique·2014
Same author

Total genomic alteration as measured by SNP-array-based molecular karyotyping is predictive of overall survival in a cohort of MDS or AML patients treated with azacitidine.

Blood cancer journal·2013
Same author

Treatment with rituximab in patients with polyneuropathy with anti-MAG antibodies.

Journal of neurology·2011
Same author

[Peripherally inserted central catheters (PICC) in onco-hematology. PICC line in onco-hematology].

Bulletin du cancer·2010
Same author

Heterogeneity of t(4;14) in multiple myeloma. Long-term follow-up of 100 cases treated with tandem transplantation in IFM99 trials.

Leukemia·2007

Area of Science:

  • Hepatology
  • Pharmacology
  • Infectious Diseases

Background:

  • Rifampicin is a key antibiotic used for treating serious bacterial infections like staphylococcal septicemia and tuberculosis.
  • Drug-induced liver injury (DILI) is a significant concern in clinical practice, necessitating careful monitoring of patients.
  • Cholestatic hepatitis, characterized by impaired bile flow, can result from various factors, including medication side effects.

Observation:

  • Three distinct cases of patients developing cholestatic hepatitis were identified.
  • These patients were undergoing treatment with rifampicin for staphylococcal septicemia (two cases) and tuberculosis (one case).
  • None of the patients had a documented history of pre-existing liver disease prior to rifampicin administration.

Findings:

Related Experiment Videos

  • The administration of rifampicin was directly associated with the onset of cholestasis in all reported cases.
  • The observed liver injury presented as cholestasis without significant hepatocellular damage.
  • No evidence of immunoallergic reactions was identified as a contributing factor to the hepatitis.

Implications:

  • Clinicians should be vigilant for signs of cholestatic hepatitis in patients treated with rifampicin, even in the absence of prior liver conditions.
  • Early recognition and potential discontinuation of rifampicin may be crucial for managing this adverse drug reaction.
  • Further research into the mechanisms underlying rifampicin-induced cholestasis is warranted to improve patient safety and treatment strategies.